ReviewDrug delivery and translational research2022
An update on microneedle-based systems for diabetes.
Review in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Biodegradable microneedles for transdermal sitagliptin delivery: in vivo insights into enhanced diabetes management.Drug delivery and translational research · 2026Article
- Bioinspired wearable polymer microneedle patches: pioneering diabetic wound therapy for the horizon.RSC advances · 2025Review
- Multifunctional dual-layer microneedles loaded with selenium-doped carbon quantum dots and Astilbin for ameliorating diabetic wound healing.Materials today. Bio · 2025Article
- Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025Review
- An Overview of Microneedles as a Drug Delivery System.Current pharmaceutical design · 2025Article
- The Promoting Effect of Animal Bioactive Proteins and Peptide Components on Wound Healing: A Review.International journal of molecular sciences · 2024Review
- Research Progress on Chitosan Microneedle Arrays in Transdermal Drug Delivery.International journal of nanomedicine · 2024Review
- 3D-Printed Microinjection Needle Arrays via a Hybrid DLP-Direct Laser Writing Strategy.Advanced materials technologies · 2023Article
- The most promising microneedle device: present and future of hyaluronic acid microneedle patch.Drug delivery · 2022Review
- Simvastatin Loaded Dissolvable Microneedle Patches with Improved Pharmacokinetic Performance.Micromachines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is one of the most serious chronic diseases today. Patients with diabetes need frequent insulin injections or blood sampling to monitor blood glucose levels. The microneedles are a painless transdermal drug delivery system, which has great advantages in achieving self-management. There have been a lot of researches on microneedles used in diabetes treatment. Microneedle-based treatment of diabetes has also changed from a simple and reliable system to a complex and efficient system. This review introduces microfluidic, glucose response, and other contents based on microneedles, and some challenges in the development of microneedles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.